162140-06-9

Basic information

• Product Name: Benzenamine, 5-chloro-N-(cyclohexylmethyl)-2-nitro-
• CAS NO: 162140-06-9
• Molecular Formula: C13H17ClN2O2
• Molecular Weight: 268.743
• Mol File: 162140-06-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenamine, 5-chloro-N-(cyclohexylmethyl)-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 5-chloro-N-(cyclohexylmethyl)-2-nitro-(162140-06-9)
• EPA Substance Registry System: Benzenamine, 5-chloro-N-(cyclohexylmethyl)-2-nitro-(162140-06-9)

Safety Data

• Hazardous Substances Data: 162140-06-9(Hazardous Substances Data)

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 2550-36-9 Cyclohexylmethyl bromide 
• 2043-61-0 cyclohexanecarbaldehyde 
• 700-37-8 4-chloro-2-fluoro-nitrobenzene 
• 3218-02-8 cyclohexylmethylamine 

Downstream Products

• 181869-96-5 Cyclohexylmethyl-(5-imidazol-1-yl-2-nitro-phenyl)-amine 
• 1365392-69-3 4-(4-(6-chloro-1-(cyclohexylmethyl)-1H-benzo[d]imidazol-2-yl)phenyl)morpholine 
• 1365392-73-9 4-(6-chloro-1-(cyclohexylmethyl)-1H-benzo[d]imidazol-2-yl)-N,N-dimethylaniline 
• 1026820-39-2 N²-Cyclohexylmethyl-4-imidazol-1-yl-benzene-1,2-diamine 
• 162140-07-0 2-amino-5-chloro-1-(cyclohexylmethyl)aniline 

Relevant articles and documents

SAR-study on a new class of imidazo[1,2-a]pyridine-based inhibitors of 5-lipoxygenase

A novel class of 5-lipoxygenase (5-LO) inhibitors characterized by a central imidazo[1,2-a]pyridine scaffold, a cyclohexyl moiety and an aromatic system, is presented. This scaffold was identified in a virtual screening study and exhibits promising inhibi

Novel AMPA receptor antagonists: Synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds

As part of our study of novel antagonists at the α-amino-3-hydroxy-5- methylisoxazole-4-propionate (AMPA) subtype of excitatory amino acid (EAA) receptors and the pharmacophoric requirements of the receptor, we designed and synthesized a series of 1-substituted 6-imidazolyl-7-nitro-, and 7- imidazolyl-6-nitroquinoxalinediones, as well as related compounds, 6a-j, 7, 11a-e, 15, and 17, which are 1- and 4-substituted analogues of 1 (YM90K), and evaluated their activity to inhibit [3H]AMPA binding from rat whole brain. On the basis of their structure-activity relationships (SAR), we deduced that the amide proton of the imidazolyl-near side of the quinoxalinedione nucleus is not essential for AMPA receptor binding, whereas that of the imidazolyl- far amide is. Further, the receptors possess size-limited bulk tolerance for their N-substituents on the imidazolyl-near amide portion. Moreover, we found that introduction of a hydroxyl group at the imidazolyl-near amide portion causes a severalfold improvement in AMPA receptor affinity over unsubstituted derivatives. Among the compounds, 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro- 2,3(1H,4H)-quinoxalinedione (11a) showed high affinity for AMPA receptor with a K(i) value of 0.021 μM, which is severalfold greater than that of 1 and NBQX (2) (1, K(i) = 0.084 μM; 2, K(i) = 0.060 μM). Compound 11a also showed over 100-fold selectivity for the AMPA receptor than for the N-methy]-D- aspartate (NMDA) receptor and the glycine site on NMDA receptor.